The role of beta receptor blockade in preventing sudden death

J Wikstrand1, M Kendall

  • 1Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska Hospital, Gothenburg University, Sweden.

European Heart Journal
|September 1, 1992
PubMed

Insights

Reducing sudden coronary death in hypertensive patients is key. Some beta-blockers, particularly beta 1-selective ones, show promise in preventing sudden cardiac death, independent of blood pressure control.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Research

Background:

  • High mortality from coronary heart disease in hypertensive patients necessitates reducing sudden cardiac death.
  • Current treatments require tailored strategies for high-risk individuals to mitigate sudden death risk.

Purpose of the Study:

  • To review treatment strategies aimed at reducing sudden death risk in hypertensive patients.
  • To evaluate the efficacy of various antihypertensive drug classes in preventing sudden coronary death.

Main Methods:

  • Review of clinical trials and large-scale secondary preventive studies.
  • Analysis of data on angiotensin converting enzyme (ACE) inhibitors, calcium antagonists, alpha-blockers, and beta-blockers.

Main Results:

  • ACE inhibitors and calcium antagonists have shown disappointing results in preventing sudden death.
  • Certain beta-blockers have demonstrated significant reductions in sudden death and other coronary events in both primary and secondary prevention.
  • Benefits of some beta-blockers are linked to beta 1-blockade, potentially independent of blood pressure reduction.

Conclusions:

  • Not all beta-blockers are equally effective in preventing sudden death; beta 1-selective agents show the most promise.
  • Lipophilic beta-blockers with central beta 1-blockade may reduce sudden death risk by enhancing cardiac vagal tone and electrical stability.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...